CN102307624A - 用于皮肤治疗的组合物 - Google Patents
用于皮肤治疗的组合物 Download PDFInfo
- Publication number
- CN102307624A CN102307624A CN2010800068593A CN201080006859A CN102307624A CN 102307624 A CN102307624 A CN 102307624A CN 2010800068593 A CN2010800068593 A CN 2010800068593A CN 201080006859 A CN201080006859 A CN 201080006859A CN 102307624 A CN102307624 A CN 102307624A
- Authority
- CN
- China
- Prior art keywords
- oil
- compositions
- acid
- skin
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 21
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 230000029663 wound healing Effects 0.000 claims abstract description 4
- 102000008186 Collagen Human genes 0.000 claims description 43
- 108010035532 Collagen Proteins 0.000 claims description 43
- 229920001436 collagen Polymers 0.000 claims description 42
- 241000628997 Flos Species 0.000 claims description 32
- 240000002030 Ethulia conyzoides Species 0.000 claims description 28
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 235000020778 linoleic acid Nutrition 0.000 claims description 11
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 9
- 230000037303 wrinkles Effects 0.000 claims description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical compound CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 claims description 4
- 244000294611 Punica granatum Species 0.000 claims description 4
- 235000014360 Punica granatum Nutrition 0.000 claims description 4
- CUXYLFPMQMFGPL-UHFFFAOYSA-N alpha-Elaeostearinsaeure Natural products C(CCCCCCCC=CC=CC=CCCCC)(=O)O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 claims description 4
- 241001072256 Boraginaceae Species 0.000 claims description 3
- 240000004528 Catalpa ovata Species 0.000 claims description 3
- 235000010005 Catalpa ovata Nutrition 0.000 claims description 3
- 240000001866 Vernicia fordii Species 0.000 claims description 3
- CUXYLFPMQMFGPL-WJTNUVGISA-N Catalpic acid Chemical compound CCCC\C=C/C=C/C=C/CCCCCCCC(O)=O CUXYLFPMQMFGPL-WJTNUVGISA-N 0.000 claims description 2
- CUXYLFPMQMFGPL-FWSDQLJQSA-N alpha-Eleostearic acid Natural products CCCCC=CC=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-FWSDQLJQSA-N 0.000 claims description 2
- IXLCRBHDOFCYRY-UHFFFAOYSA-N dioxido(dioxo)chromium;mercury(2+) Chemical compound [Hg+2].[O-][Cr]([O-])(=O)=O IXLCRBHDOFCYRY-UHFFFAOYSA-N 0.000 claims description 2
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 241001071905 Echium Species 0.000 abstract description 5
- 240000001432 Calendula officinalis Species 0.000 abstract description 4
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 abstract description 3
- 235000003880 Calendula Nutrition 0.000 abstract description 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 abstract 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 abstract 2
- 108010050808 Procollagen Proteins 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 74
- 235000019198 oils Nutrition 0.000 description 74
- 210000003491 skin Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 231100000952 EST-1000 RHE Toxicity 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 102000012422 Collagen Type I Human genes 0.000 description 8
- 108010022452 Collagen Type I Proteins 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 206010040954 Skin wrinkling Diseases 0.000 description 7
- 239000002199 base oil Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003796 beauty Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 101150033839 4 gene Proteins 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- -1 ester aliphatic monocarboxylic acid Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 101150090724 3 gene Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000183672 Echium plantagineum Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000001314 profilometry Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000001466 Ribes nigrum Nutrition 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 240000002299 Symphytum officinale Species 0.000 description 2
- 235000005865 Symphytum officinale Nutrition 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 102000054350 human CHI3L1 Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229940093609 tricaprylin Drugs 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- CUXYLFPMQMFGPL-WPOADVJFSA-N (9Z,11E,13E)-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C/CCCCCCCC(O)=O CUXYLFPMQMFGPL-WPOADVJFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000134716 Hodgsonia macrocarpa Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241001098109 Jacaranda mimosifolia Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 241000605385 Ruscus Species 0.000 description 1
- 244000295490 Salvia japonica Species 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000438 stratum basale Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 210000000437 stratum spinosum Anatomy 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- PBSRSWFGYPZDAU-FFIPNUABSA-H trimagnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-oxido-5-oxo-2h-furan-4-yl] phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] PBSRSWFGYPZDAU-FFIPNUABSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供一种组合物,其包含衍生自例如蓝蓟油的亚麻油酸(或其酯),和另外的脂质(衍生自例如金盏花油),所述另外的脂质增加亚麻油酸的前胶原化作用。该组合物用于减少人类或动物皮肤老化的常见体征或创伤愈合的方法。
Description
技术领域
本发明涉及局部施用于人体或动物体的组合物。特别地,本发明涉及包含天然产生的植物种子油的组合物以刺激皮肤细胞中的胶原合成。这样的组合物用于皮肤的治疗和创伤愈合。
背景技术
大部分植物种子油(脂质)是脂肪酸和甘油的甘油三酯。脂肪酸可以是饱和的、单-不饱和的或多-不饱和的。通过刺激皮肤细胞中的胶原生成而在皮肤症状的治疗中有价值的植物种子油是那些含有多-不饱和脂肪酸的种子油。脂肪酸是以酯特别是甘油三酯的形式在动物或植物脂肪或油中天然产生的脂肪族单羧酸。由于认识到它们在例如人类营养中的有益性,大量的努力投入在从它们的天然来源中提取含有多-不饱和脂肪酸的甘油三酯。
亚麻油酸(SDA)是n3家族的多不饱和脂肪酸,其在常规命名法中被描述为C18:4n3。其以甘油的三酯(或甘油三酯)的形式可见于黑醋栗、红醋栗和醋栗果仁的油。WO97/46220(Croda International Plc)公开了SDA甘油三酯可以来源于从紫草科(Boraginaceae)植物家族的种子提取的油,该油本身可以用于饮食的、美容的和医疗保健产品,而不需另外的处理或纯化。SDA的一个特别丰富的来源是蓝蓟属(Echium)的种子。
US 6,340,485(Croda International Plc)公开了包含1至20重量%的从紫草科植物种(特别是蓝蓟属种)的种子提取的油,该油包含5至20%SDA甘油三酯和80至95%的其它脂肪酸甘油三酯。据称该组合物特别适合于口服或局部给药,并且适合于饮食的、美容的、药物的和医疗保健用途。特别地,据称所述组合物特别有利于用于治疗皮肤炎症和特别是晒伤。尽管承认还没有完全理解晒伤的发病机理,其假设包括类花生酸和细胞因子(其可从SDA代谢得到)的炎症介质的释放似乎是重要的。
大量其它现有技术参考文献公开了在组合物中的蓝蓟油(Echiumoil)用于治疗皮肤的用途,例如:WO 2008/00074 A2(L’Occitane)、US2008/0213357 A1(Hebard)和WO 02/092073 A1(Martek BiosciencesBoulder Corporation)。在EP 0 460 848 A1(Efamol Holdings Plc.)中也公开了包含蓝蓟油活性组分(亚麻油酸和γ-亚麻酸)的组合物。
US 2004/0161435 A1(Gupta)公开了美容面膜组合物,其促进过量脂肪减少、脂肪团控制或肌肉和皮肤调色效应。一个典型的组合物包含作为活性组分的迷迭香、万寿菊、鼠尾草、人参、圣约翰木瘤(St.John’swart)和花竹柏的提取物。
万寿菊提取物作为美容组合物中的活性组分以对抗皮肤老化体征也公开在以下现有技术参考文献中:FR 2902334 A1(Laboratoire Nuxe)、JP 2001253817 A(Nagase)和WO 2004/022034 A1(Dermaphyt)。
RO 118256 B(Farmec SA)公开了抗皱美容面霜,其包含尤其是来自金盏花(Calendula)的叶和花柄的提取物。将油(例如花生油)应用于提取,但是从油是产生于金盏花种子的意义上说不能认为所述组合物包含金盏花油(Calendula oil)。
皮肤老化是两个不同过程的结果,外源的(由环境因素引起例如UVA/UVB暴露、生活方式、吸烟、过量酒精摄取和饮食)和内源的或随时间老化(其中涉及遗传因素)。皮肤老化的常见结果是皮肤色调和弹性的消失、脱水、皮肤粗糙、老年斑、细纹(lines)和皱纹(wrinkles)。众所周知涉及皮肤下垂、细纹和皱纹产生的主要因素是皮肤胶原的随时间减少。另外,环境因素可以刺激涉及胶原分解的蛋白水解酶的产生。
发明内容
本发明的第一个方面提供用于局部施用于人体或动物体的组合物,其包含亚麻油酸或其酯,以及另外的增加亚麻油酸的前胶原化作用的脂质。
在一个优选的具体实施方案中所述另外的脂质是共轭的十八碳三烯酸(CODTA)或其酯。最著名的天然产生的CODTAs列表如下:
CODTA | 构型 | 来源 |
金盏花酸 | 8t10t12c-18:3 | 金盏花(Calendula officinalis) |
梓树酸 | 9t11t13c-18:3 | 梓树(Catalpa ovata) |
α-桐酸 | 9c11t13t-18:3 | 油桐(Aleurites fordii) |
蓝花楹酸 | 8c10t12c-18:3 | 蓝花楹(Jacaranda mimosifolia) |
石榴酸 | 9c11t13c-18:3 | 石榴(Punica granatum) |
优选地,所述亚麻油酸由提取自紫草科植物家族的种子的油提供,并且最优由提取自蓝蓟属车前叶蓝蓟(Echium plantagineum)的种子的油提供。所述油可以以0.1%至10%w/w,优选约4.95%w/w的量存在。
所述另外的脂质优选以0.005%至1%w/w,更优选0.01%至0.1%w/w,最优选约0.05w/w的量存在。
本发明组合物也可以包含生理学上可接受的载体。例如,它们可以另外地包含一种或多种保湿剂、软化剂、乳化剂、防腐剂、分散剂、粘度改进剂、草本提取物、溶剂、螯合剂、抗氧化剂、维生素C、维生素C的酯、抗坏血酸棕榈酸酯、抗坏血酸磷酸酯镁、防水剂、pH调节剂、香料、和氨基酸、肽或蛋白质。
所述组合物可以制成固体、液体、气雾剂、霜剂、乳剂、胶体或以胶囊的形式。
本发明的第二个方面提供减少人类或动物皮肤老化的常见体征的方法,其包含施用于所述皮肤与生理学上可接受的载体联合的任何如上定义的所述组合物。
本发明的第三个方面提供治愈人体或动物体中创伤的方法,其包含施用于创伤部位与生理学上可接受的载体联合的任何如上定义的所述组合物。
根据本发明的第四个方面,此处提供包含亚麻油酸(优选以蓝蓟油的形式提供)或金盏花油或其混合物的组合物,其用于刺激皮肤细胞中胶原合成。
本申请人惊人的实现是蓝蓟油和金盏花油单独(或联合)刺激皮肤细胞中的胶原合成。之前,该作用机理还是未知。本发明实现的结果是所述组合物可以用作美容产品,并且也可用作创伤敷料中的成分以加速创伤愈合。
值得注意的是所述活性组分是金盏花油,并不是在现有技术中采用的金盏花提取物。所述提取物是金盏花的花的煎剂(通常在植物油例如向日葵种子油或花生油中),然而所述油可以通过磨碎金盏花植物的种子并使用合适的溶剂,例如己烷或超临界二氧化碳提取缩小(diminuted)的种子制得。或者,所述油可以通过简单地冷压缩金盏花种子得到。金盏花提取物不包含金盏花酸,然而金盏花油包含金盏花酸。
根据本发明的另一方面,此处提供包含亚麻油酸(优选以蓝蓟油的形式提供)的组合物,其用于减少经皮水分流失。
根据本发明的又另一方面,此处提供包含亚麻油酸(优选以蓝蓟油的形式提供)的组合物,其用于减少皮肤皱纹。
附图说明
本发明大量优选的具体实施方案现将参考以下附图描述,其中:
图1是显示EST-1000表皮模型的图;
图2是显示各种油对胶原1基因表达的作用的柱状图;
图3是显示各种油对胶原1和胶原4基因表达的作用的柱状图;
图4是显示各种制备产品对胶原1和胶原4基因表达的作用的柱状图;
图5是显示各种测试油对胶原3基因表达的作用的柱状图;和
图6是显示各种制备产品对胶原3基因表达的作用的柱状图。
具体实施方式
实施例
A]含有蓝蓟油的制剂
1、保湿乳液
方法
分别加热油相和水相至65-70摄氏度。在搅拌下将水相加入至油相并冷却。在35摄氏度加入香料、防腐剂、着色剂和任选成分例如植物提取物。
2、抗皱晚霜
方法
分别将相A和B加热至约80摄氏度。搅拌相B至相A并匀质化。在搅拌下将相C加入至相A+B并匀质化。冷却至40摄氏度。
3、轻薄日霜
方法
分别将油和水相加热至65-70摄氏度。在搅拌下将水相加入至油相。搅拌至冷却,在60摄氏度用三乙醇胺将pH调节至约7。
4、深层皱纹处理
方法
混合所有相A的组分,在70摄氏度在搅拌下将相B加入至相A。允许冷却至40摄氏度并在搅拌下加入相C。如需要,用稀释的氢氧化钠水溶液调节pH。
B]用于增加皮肤细胞中胶原合成的脂质组合物
使用以下实验方法得到来自皮肤细胞(纤维母细胞或角质细胞)的胶原合成的体外数据。将人类纤维母细胞或角质细胞接种于24孔板并在常规介质中培养直至约50%融合。最初制备测试溶液(蓝蓟油、金盏花油或两种油的混合物)为二甲基亚砜(DMSO)中1%并超声(sonification)5分钟。在加入至细胞前将浓缩的油溶液用常规介质连续稀释并超声(5分钟)。介质中油的浓度为0.00001%、0.0001%或0.001%。
将纤维母细胞和角质细胞与油培养3天或7天(在7天培养的第3天更换含有油的介质)。通过加入甲醛溶液(3.7%)固定细胞,然后用磷酸盐缓冲盐水(PBS)洗涤三次。将胶原特异性染色;苦味酸中的天狼星红(0.1%)加入至孔中约18小时。除去未结合的染料并用自来水洗涤孔直至澄清。干燥染料,然后在温和震摇下用“Destain”(甲醇中0.2MNaOH 1∶1)洗脱15分钟。使用读板仪(plate reader)测定(490nm)洗出液的光密度。
结果
与测试油和DMSO对照培养(3天)后纤维母细胞的
胶原产生(光密度/490nm)
与测试油和DMSO对照培养(3天)后角质细胞的
胶原产生(光密度/490nm)
如纤维母细胞中可以看出两种油均以21.7%-30.0%之间增加胶原合成。在角质细胞中作用显著性较弱,然而在低的浓度两种油再次增加胶原合成(金盏花油-27.2%,蓝蓟油-16.0%)。
C]轮廓测定法研究以测定在减少细纹和皱纹中美容皮肤血清的功
效
对22个女性受试者进行了为期六周的家用研究。在基线(Baseline)时和六周使用期结束时进行经皮水份散失度(TEWL)测量和皮肤感观。使用六周后所有受试者也完成了消费者知觉调查问卷。该研究的目的是确定该测试材料,面部皮肤血清F1/1445D,是否在减少细纹和皱纹中有效。
皮肤血清F1/1445D是包括5%w/w蓝蓟油具有以下配方(所有量是以%w/w计)的组合物:
结果
受试者给出的评论基本上是正面的。然而,大部分的评审不喜欢血清的香味。
统计报告
1、方法学
位于因弗雷斯克(Inveresk)的医学数据科学部门(Medical DataSciences Department),查尔斯河公司(Charles River Company)进行了统计学分析。使用统计软件包SAS(v8.2)进行统计学分析。
轮廓测定法和TEWL评价对于22个志愿者是可得的。在基线和第六周进行读数。处理施用于面部每日早晚两次持续6周。在基线和第6周从面部每侧的太阳穴区域进行皮肤表面的脱落物和蒸发计读数。
1.1、方案中设计的统计学方法
分析的主要测试标的是对于每个粗糙参数评价(Sa、Sq、Sp、Sv、St和Sz)自基线(处理前)至第6周的变化,其从轮廓曲线仪获得。
使对于每个粗糙参数自基线至第6周的变化经过使用SAS程序PRC MIXED的协方差(ANCOVA)技术的参数分析。ANCOVA测试自基线至第6周的变化等于零的虚假设。模型包括侧面(左侧或右侧太阳穴区域)的条件和基线值,涉及到随机作用。自基线至第6周调节的平均值改变了,对于每个粗糙参数呈现出相应的95%的置信区间和p值。
进行探索性分析以评价异常值的影响。如果对于正态分布的假设保留怀疑,将使用相应的非参数方法(即,广义森检定,适用对于以上分析可变的分级应答)。
次要测试标的是对于TEWL自基线至第6周的变化,其使用对于主要测试标的相同的技术进行分析。
1.2、设计的方法的变化
另外,调整的平均值自基线至第6周变化,对于每个粗糙参数由侧面分别地呈现相应的95%置信区间和p值(使用如以上详细描述相同的ANCOVA模型),由于对于所有粗糙参数左侧和右侧太阳穴区域之间的基线值的平均值变化存在明显不同。
2、自基线变化的第6周的结果
2.1、自基线的变化
表I-轮廓测定法和TEWL参数的统计学分析
*除去末端观测值后的结果
表1显示对于分析的粗糙和TEWL参数的结果。所有粗糙参数对于TEWL自基线至第6周具有统计学显著的减少,还发现为自基线至第6周的统计学显著的减少。
对于参数Sp、St、Sz和TEWL常态的假设是令人满意的。对于余下的参数Sa、Sq和Sz在每个分析中具有一个异常值的证据(评审号19672,Sa和Sq的右侧,和评审号20271,Sv的左侧)。除去有关的异常值进行第二次分析,并且除去异常值后常态的假设是令人满意的。
3、侧面自基线变化的第6周的结果
3.1、侧面自基线的变化
对于所有粗糙参数左侧和右侧太阳穴区域之间基线值的平均变化有明显不同。左侧和右侧值之间的平均不同甚至达到了统计学显著性,对于参数Sa、Sq和Sz在5%的水平。因此表II显示对于所有分析的粗糙和TEWL参数左侧和右侧太阳穴区域分别的结果。
表II-侧面轮廓测定法和TEWL参数的统计学分析
*除去末端观测值后的结果
对于左侧太阳穴区域所有粗糙参数自基线至第6周具有统计学显著的减少,然而对于任何粗糙参数右侧太阳穴区域没有发现该减少具有显著性。对于TEWL,两个太阳穴区域自基线至第6周均发现统计学显著的减少。
对于参数Sp、St、Sz和TEWL常态的假设是令人满意的。对于余下的参数Sa、Sq和Sz在每个分析中具有一个异常值的证据(评审号19672,Sa和Sq的右侧,和评审号20271,Sv的左侧)。除去有关的异常值进行第二次分析,并且除去异常值后常态的假设是令人满意的。
D]脂质制剂对胶原1含量的作用的分析
方案
如所示脂质制剂局部施用于EST-1000表皮模型(CellsystemsBiotechnologie Vertrieb GmbH)。该模型由初级人类角质细胞组成并在由基底细胞层(基底层(stratum basale))、棘(spinous)(或刺(prickle))细胞层(棘层(stratum spinosum))、颗粒层(粒层(stratum granulosum))和最后角质层(角质层(stratum corneum))组成的整个表皮层展现出生理分化模式。角质层赋予表皮特有的屏障能力。屏障功能被用作主要的质量控制。EST-1000模型通常在气升条件(airlift condition)下培育14天。为了促进较长时间的治疗和观察,在整个该研究中使用11天气升培育的皮肤模型。
预实验运行测试胶原I ELISA
在研究开始前,每个使用EST-1000模型测试用于胶原I蛋白分析的方案和检测系统。不处理皮肤模型。将胶原蛋白分泌至细胞外基质(ECM)。因此,该蛋白需要从ECM中提取。提取方案涉及用胃蛋白酶和弹性蛋白酶处理皮肤模型。通过ELISA测量经提取释放的蛋白质部分的浓度并直接与胶原含量相关联。
提取方案
A)胃蛋白酶消化
1、从嵌入物中切出具有表皮的膜(此后称作EST)。
2、在4℃在2.0mL杯子中于重蒸馏水(0.5mL)中培养EST。
3、在10.000rpm和4℃离心(Biofuge fresco,Heraeus)3分钟。
4、将EST转移至0.1mL胃蛋白酶缓冲液中(0.05M醋酸中0.1mg/mL)。
5、于4℃小心震摇培养过夜。
6、在10.000rpm和4℃离心(Biofuge fresco,Heraeus)3分钟。
7、将上清液转移至含有0.1mL缓冲的常规山羊血清的收集管中。
B)弹性蛋白酶消化
1、在0.1mL弹性蛋白酶缓冲液(0.1M Tris-0.15M NaCl-5mMCaCl2 pH 7.8中0.1mg/mL)中培养EST。
2、在4℃小心震摇培养过夜。
3、在10.000rpm和4℃离心(Biofuge fresco,Heraeus)3分钟。
4、从步骤7的胃蛋白酶消化合并上清液于收集管中。
C)中和
通过加入1M Tris缓冲液(上清液体积的1/50)中和收集管中合并的上清液的pH。
D)胶原ELISA
以上描述的胶原提取方案改进自胶原I检测试剂盒(Chondrex Inc.#6008)的手册中描述的胶原I提取方案。
按照胶原I检测试剂盒(Chondrex Inc.#6008)的生产者给出的方案进行胶原I的测定。
基因表达分析
通过RT-PCR(反转录酶聚合酶链式反应)使用Taqman基因表达试验(Applied Biosystems)分析编码胶原I基因的表达。如上所述从嵌入物中切割EST。切割的EST在4℃储存于RNAlater(Ambion)直至RNA制备。为了RNA制备使用Precellys(Peqlab Biotechnologie GmbH,德国)分解组织。将细胞于RLT缓冲液(RNeasy-试剂盒,Qiagen)中溶解。通过三个不同的方案从这些溶解产物纯化RNA。
1、RNeasy(Qiagen)
2、Trizol提取(Invitrogen,标准苯酚提取方案)
3、氯仿提取(标准方案)
使用所有三个方法可以从未处理的EST-1000分离充足的RNA。在从用测试制剂处理的EST纯化RNA的两个样本中RNeasy方法均失败。使用Trizol方案得到了同样的结果。使用氯仿提取(标准分子生物学方案),也可以从处理的EST分离RNA。
因此,所有通过RT-PCR分析的RNA均通过氯仿提取纯化。
结果
通过所有的处理诱导了胶原I基因的表达(见图2)。特别地,对于蓝蓟油与金盏花油的组合和蓝蓟油与石榴种子油的组合观察到相对高倍的变化。
E]含有蓝蓟油和金盏花油的产品对EST1000
TM
皮肤模型中基因表
达的作用
概要
在EST1000TM皮肤模型(3)中评价八个含有蓝蓟油和金盏花油的测试油、2个商业可得的美容洗液(1)和2个实验用洗液(2)。使用的测试油是甘油三辛酸/癸酸酯(Crodamol GTCC或MCT)作为惰性载体油。总的目的是确认早期结果,该结果显示蓝蓟/金盏花油混合物在促进皮肤胶原合成中是增效的。使用反转录-聚合酶链式反应(RT-PCR)分析大量在皮肤细胞中胶原合成中涉及的基因。
注释
1、商业可得美容洗液是“防护和完美紧致美颜血清(Protect andPerfect Intense Beauty Serum)”(博姿公共有限公司(Boots CompanyPLC),诺丁汉,英国)和“高级夜间修复浓缩液(Advanced Night RepairConcentrate)”(雅诗兰黛(Estee Lauder DIST.),纽约NY,美国)。两个产品均满足“保湿”或“皮肤修复”要求并且是品牌领导者。
2、实验用洗液是含有单独的蓝蓟油或蓝蓟油和金盏花油的混合物的全制备产品(配方1化妆品发展有限责任公司(Formula 1 CosmeticDevelopments Company Ltd.),西萨塞克斯郡,英国)。
3、EST1000TM皮肤模型是3维分化型皮肤细胞模型或“活皮肤等价物”。
配方
实验用洗液(参见下列表III中种子#2和种子#3)具有以下组成:
种子#2
INCI名称 | 总INCI配方 |
水(AQUA) | 75.147 |
甘油三辛酸/癸酸酯 | 10 |
车前叶蓝蓟油 | 5 |
C12-16醇 | 2.48 |
鲸蜡硬脂醇 | 1.5 |
甘油 | 0.9 |
棕榈酸 | 0.76 |
卵磷脂 | 0.76 |
山梨醇 | 0.75 |
苯氧乙醇 | 0.592 |
钠羟基吡咯烷酮 | 0.54 |
菊粉十二烷基氨基甲酸酯 | 0.5 |
黄原胶 | 0.3 |
菌类植物胶 | 0.3 |
乳酸钠 | 0.21 |
苯甲酸 | 0.096 |
透明质酸钠 | 0.06 |
脱氢乙酸 | 0.056 |
植酸 | 0.025 |
乙基己基甘油 | 0.016 |
聚氨基丙基双胍 | 0.008 |
种子#3
方案
EST1000的处理方案
生存能力测试:
一式三份将20μL测试油施用于EST1000的表面。施用后在37℃、5%CO2和100%湿度培养EST过夜(18h)。通过MTT测试测量EST1000的能见度。
基因表达分析:
一式三份将20μL测试油施用于EST1000的表面。施用后在37℃、5%CO2和100%湿度培养EST过夜(18h)。从嵌入物中切出表皮,并将组织固定于RNAlater(Ambion)用于RNA制备。制备RNA并控制分离的RNA的浓度和质量。通过RNA在260和280nm的光学密度间的比例测定质量。多于或等于1.8的比例代表好的RNA质量。
通过定量实时RT-PCR(Taqman)分析感兴趣的三个基因(Col1A1,Col3A1,Col4A6)的基因表达。
MTT-测试
通过MTT-测试测量EST1000的生存能力,所述MTT-测试是基于通过线粒体还原酶的3-4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)的还原。MTT的还原导致紫色的甲瓒晶体的形成,其溶于异丙醇。甲瓒的量可以在550nm测定并且直接与生存能力相关联。以被定义为100%的非处理的对照的百分比计算处理的表皮模型的生存能力。
RT-PCR
根据应用生物系统公司方案(Applied Biosystems protocol)(Taqman)进行RT-PCR分析。简言之:将1μg RNA转录为cDNA,其用作模板与基因特异性引物和探针用于实时RT-PCR。
结果
下列表III显示了主要结果,然后将主要结果分离至随后的表。使用蓝蓟油和金盏花油“模型化合物(model compound)”混合物,关于胶原1、胶原3和胶原4基因的表达观察到显著的增效作用。在全制备实验用洗液中也观察到了该结果。
表III
基因
●胶原1A1基因编码皮肤中的最大量的蛋白、腱和骨,其是组织通过修复治愈时的最终产物。
●在更强的1型胶原产生之前胶原3A1在年轻的纤维细胞中产生。
●胶原4A6,在基底层中的主要蛋白。该基因编码4型胶原的六个亚型之一。
E1]MCT载体油中的油对胶原1和胶原4基因表达变化的作用
评价了四个油:单独的载体油(Crodamol GTCC)、含有金盏花油的载体油(0.05%)、含有蓝蓟油的载体油(5%)、含有蓝蓟油(4.95%)和金盏花油(0.05%)的载体油。下列表IV中显示了结果并在图3中用图表示。
表IV MCT载体油中的油对胶原1和胶原4基因表达的作用
E2]施用的商业产品在EST1000
TM
皮肤模型中对胶原1、3和4基
因表达的作用
两个商业可得的皮肤护理产品雅诗兰黛的“高级夜间修复浓缩液”和来自博姿公司的“7号防护和完美紧致美颜血清”。测试了两个实验用、全制备洗液,含有蓝蓟油作为生物活性脂质的种子#2和含有蓝蓟油(4.95%)和金盏花油(0.05%)的种子#3。对于胶原1和4的这些测试的结果在下列表V中显示并在图4中用图表示:
表V制备产品对胶原1和胶原4基因表达的作用
以上对胶原3的测试的结果在下列表VI中显示并在图5中用图表示。
表VI制备产品对胶原3基因表达的作用
Claims (17)
1.一种局部施用于人体或动物体的组合物,其包含亚麻油酸或其酯,以及增加亚麻油酸前胶原化作用的另外的脂质。
2.根据权利要求1所述的组合物,其中所述另外的脂质是共轭十八碳三烯酸或其酯。
3.根据权利要求1或2所述的组合物,其中所述另外的脂质是金盏花酸、梓树酸、α-桐酸、蓝花楹酸、石榴酸、任何前述酸的酯、或任何前述的组合。
4.根据权利要求3所述的组合物,其中所述酸分别提取自金盏花、梓树、油桐、蓝花楹和石榴。
5.根据前述权利要求任意一项所述的组合物,其中所述亚麻油酸通过提取自紫草科家族的种子的油提供。
6.根据权利要求5所述的组合物,其中所述油的量为0.1%至10%w/w。
7.根据前述权利要求所述的组合物,其另外地包含生理学上可接受的载体。
8.根据前述权利要求任意一项所述的组合物,其中所述另外的脂质的量为0.005至1%w/w。
9.根据前述权利要求任意一项所述的组合物,其用于实施于人体或动物体的治疗方法中。
10.根据权利要求1至8任意一项所述的组合物,其用于减少人类或动物皮肤老化的常见体征的方法中。
11.根据权利要求1至8任意一项所述的组合物,其用于创伤愈合的方法中。
12.一种减少人类或动物皮肤老化的常见体征的方法,其包括施用于所述皮肤与生理学上可接受载体联合的包含蓝蓟油的组合物或者根据权利要求1至8任意一项所述的组合物。
13.一种治愈人体或动物体创伤的方法,其包括施用于创伤部位与生理学上可接受载体联合的包含蓝蓟油的组合物或者根据权利要求1至8任意一项所述的组合物。
14.一种减少经皮水份流失的方法,其包括施用于创伤部位与生理学上可接受载体联合的包含蓝蓟油的组合物或者根据权利要求1至8任意一项所述的组合物。
15.一种包含蓝蓟油或金盏花油或其混合物的组合物,其用于刺激皮肤细胞中胶原合成。
16.一种包含蓝蓟油的组合物,其用于减少经皮水份流失。
17.一种包含蓝蓟油的组合物,其用于减少皮肤皱纹。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0902040.5 | 2009-02-06 | ||
GBGB0902040.5A GB0902040D0 (en) | 2009-02-06 | 2009-02-06 | Composition for treatment of skin |
PCT/GB2010/000215 WO2010089566A2 (en) | 2009-02-06 | 2010-02-05 | Composition for treatment of skin |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102307624A true CN102307624A (zh) | 2012-01-04 |
Family
ID=40469750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010800068593A Pending CN102307624A (zh) | 2009-02-06 | 2010-02-05 | 用于皮肤治疗的组合物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US9403042B2 (zh) |
EP (1) | EP2393557A2 (zh) |
CN (1) | CN102307624A (zh) |
GB (1) | GB0902040D0 (zh) |
WO (1) | WO2010089566A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102164577A (zh) * | 2008-08-01 | 2011-08-24 | E·S·L·I·有限公司 | 用于加速胶原蛋白生成的组合物 |
CN107536829A (zh) * | 2016-06-23 | 2018-01-05 | 中国医药大学 | α‑桐油酸抗老化的用途 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201010638D0 (en) | 2010-06-24 | 2010-08-11 | Seeds Lp | Composition for treatment of skin |
WO2013180490A1 (ko) * | 2012-05-30 | 2013-12-05 | 한국생명공학연구원 | 유동추출물, 이의 분획물 또는 이로부터 분리한 디테르펜 화합물을 유효성분으로 함유하는 피부노화 방지 및 개선용 약학적 조성물 |
EP3212288B1 (en) * | 2014-10-31 | 2024-04-03 | Pomega, Inc. | Formulations containing pomegranate seed oil, rosa canina fruit oil and inula viscosa oleoresin or extract |
US10617613B2 (en) * | 2018-04-30 | 2020-04-14 | L'oreal | Leave-on hair styling compositions and methods of use |
KR20210038636A (ko) | 2018-07-27 | 2021-04-07 | 존슨 앤드 존슨 서지컬 비전, 인코포레이티드 | 눈 치료용 조성물 및 방법 |
US10966948B2 (en) | 2019-07-23 | 2021-04-06 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11197841B2 (en) | 2019-07-23 | 2021-12-14 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
US11969454B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6340485B1 (en) * | 1996-06-03 | 2002-01-22 | Croda International Plc | Compositions and uses thereof |
US20070280898A1 (en) * | 2006-06-06 | 2007-12-06 | P & H Enterprises Of Marco Inc. | Dermatological compositions |
CN102164577A (zh) * | 2008-08-01 | 2011-08-24 | E·S·L·I·有限公司 | 用于加速胶原蛋白生成的组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9012651D0 (en) | 1990-06-06 | 1990-07-25 | Efamol Holdings | Essential fatty acid treatment |
EP0928185B1 (en) | 1996-06-03 | 2003-09-03 | CRODA INTERNATIONAL plc | Compositions and uses thereof |
JP2001253817A (ja) | 2000-03-10 | 2001-09-18 | Nagase & Co Ltd | コラーゲン合成促進剤およびその製造方法ならびにコラーゲン合成促進剤を含有する皮膚外用剤。 |
US20030175914A1 (en) * | 2000-09-20 | 2003-09-18 | Kai-Uwe Baldenius | Method for producing glycerides of conjugated, polyunsaturated fatty acids on the basis of their alkyl esters |
MXPA03010467A (es) | 2001-05-14 | 2004-12-06 | Martek Biosciences Boulder Corp | Produccion y uso de una fraccion polar rica en lipidos que contienen acido estearidonico y acido gama-linolenico proviniente de semillas y microbios. |
PL355298A1 (en) | 2002-08-01 | 2004-02-09 | DERMAPHYT Sp.z o.o. | Dermatological preparation for curing skin defects |
US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
FR2873295B1 (fr) * | 2004-07-26 | 2006-12-01 | Expanscience Sa Lab | Utilisation d'au moins un triene d'acide gras conjugue pour la preparation d'un medicament destine au traitement de l'inflammation |
WO2007004229A2 (en) * | 2005-07-06 | 2007-01-11 | Rimonest Ltd. | Methods of using pomegranate fractions for skin repair |
US20070150773A1 (en) | 2005-12-19 | 2007-06-28 | Nortel Networks Limited | Extensions to SIP signaling to indicate SPAM |
FR2902334B1 (fr) * | 2006-06-16 | 2011-09-30 | Nuxe Lab | Utilisation d'un extrait de souci dans une composition cosmetique. |
FR2903014B1 (fr) | 2006-06-30 | 2008-09-26 | Occitane L | Composition cosmetique a base d'acide gras polyinsatures et ses utilisations |
US20080213357A1 (en) | 2007-02-12 | 2008-09-04 | Andrew Bruce Hebard | Plant Derived Lipid Useful for Nutraceutical and Cosemeceutical Applications |
-
2009
- 2009-02-06 GB GBGB0902040.5A patent/GB0902040D0/en not_active Ceased
-
2010
- 2010-02-05 CN CN2010800068593A patent/CN102307624A/zh active Pending
- 2010-02-05 US US13/147,248 patent/US9403042B2/en active Active
- 2010-02-05 WO PCT/GB2010/000215 patent/WO2010089566A2/en active Application Filing
- 2010-02-05 EP EP10703195A patent/EP2393557A2/en not_active Withdrawn
-
2016
- 2016-07-28 US US15/222,773 patent/US20170172964A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6340485B1 (en) * | 1996-06-03 | 2002-01-22 | Croda International Plc | Compositions and uses thereof |
US20070280898A1 (en) * | 2006-06-06 | 2007-12-06 | P & H Enterprises Of Marco Inc. | Dermatological compositions |
CN102164577A (zh) * | 2008-08-01 | 2011-08-24 | E·S·L·I·有限公司 | 用于加速胶原蛋白生成的组合物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102164577A (zh) * | 2008-08-01 | 2011-08-24 | E·S·L·I·有限公司 | 用于加速胶原蛋白生成的组合物 |
CN107536829A (zh) * | 2016-06-23 | 2018-01-05 | 中国医药大学 | α‑桐油酸抗老化的用途 |
Also Published As
Publication number | Publication date |
---|---|
GB0902040D0 (en) | 2009-03-11 |
WO2010089566A3 (en) | 2011-03-31 |
US20110293751A1 (en) | 2011-12-01 |
US9403042B2 (en) | 2016-08-02 |
WO2010089566A4 (en) | 2011-05-26 |
US20170172964A1 (en) | 2017-06-22 |
EP2393557A2 (en) | 2011-12-14 |
WO2010089566A2 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102307624A (zh) | 用于皮肤治疗的组合物 | |
CN101180030B (zh) | 化妆品及皱纹改善剂 | |
CN101111289A (zh) | 防皱化妆品组合物 | |
CN105687055A (zh) | 一种眼部修护精华液及其制备方法 | |
CN103037880B (zh) | 含有构树的提取物的组合物 | |
TW201206494A (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
CN110200884A (zh) | 一种具有控油和修复功效的组合物及其制备方法和在化妆品中的应用 | |
JP2010514774A (ja) | 肌の状態および外観を改善するための組成物およびその使用方法 | |
EP2953611A1 (fr) | Utilisation d'une composition comprenant un perséose d'avocat dans la protection des cellules souches épidermiques | |
CN113509400A (zh) | 皮肤用组合物及其应用、美白提亮化妆品组合物及其制备方法 | |
CN103180016B (zh) | 包含泡桐素和/或泡桐属提取物的组合物及其用途 | |
CN106794136A (zh) | 丹参提取物和烟酸和/或烟酰胺的组合产品的去糖基化作用 | |
CN103330658A (zh) | 具有修复受损皮脂膜、舒缓皮肤压力的护肤组合物 | |
JP2005330281A (ja) | 皮膚弾力増進用化粧料組成物 | |
CN103930560A (zh) | 从藻类中生产4-氨基丁酸的方法 | |
JP2004091376A (ja) | 表皮角化正常化剤及びこれを含有する皮膚外用剤 | |
Saewan et al. | Anti-aging efficacy of Thai red rice callus cosmetic product | |
FR3018449A1 (fr) | Utilisation cosmetique d'un extrait de mirabilis jalapa, ingredient actif et composition cosmetique correspondantes | |
KR100678864B1 (ko) | 천궁 추출물 및 카르니틴을 유효성분으로 함유하는 피부미백용 화장료 조성물 | |
FR3034667A1 (fr) | Composition cosmetique et/ou dermatologique contre l'acne | |
CN103491943B (zh) | 包含榕树、莲属植物和三叶草浆液级分的组合物(老化) | |
KR102433733B1 (ko) | 쑥부쟁이 유래 캘러스 추출물 및 그 배양액을 유효성분으로 포함하는 피부 미백용 조성물 | |
EP3871658A1 (fr) | Principe actif comprenant un extrait d'avoine noire et un extrait de bugrane epineuse et utilisations cosmetiques notamment anti-grisonnement | |
EP2124871A2 (en) | Formulation for increasing the activity of a plant extract for cosmetic use and cosmetic preparation which comprises the same | |
CH706016A2 (de) | Auf Stammzellen der Epidermis und Dermis und auf deren Mikro-Umgebung wirkende kosmetische Zusammensetzung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: American New York Applicant after: Seed Group Corporation Address before: American New York Applicant before: Seeds LP |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SEED CO. TO: SEED GROUP CO. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120104 |